key: cord-0899887-ejowefav authors: Clara Di Germanio, C. D.; Simmons, G.; Kelly, K.; Martinelli, R.; Darst, O.; Azimpouran, M.; Stone, M.; Hazegh, K.; Grebe, E.; Zhang, S.; Ma, P.; Orzechowski, M.; Livny, J.; Hung, D. T.; Vassallo, R. R.; Busch, M. P.; Dumont, L. J. title: SARS-CoV-2 Antibody persistence in COVID-19 convalescent plasma donors date: 2021-03-26 journal: nan DOI: 10.1101/2021.03.24.21254260 sha: 5f653082ba13c0a98dea87c15b87ed8ea9e76c8a doc_id: 899887 cord_uid: ejowefav Background Antibody response duration following SARS-CoV-2 infection tends to be variable and depends on severity of disease and method of detection. Study design and methods COVID-19 convalescent plasma (CCP) from 18 donors was collected longitudinally for a maximum of 63 - 129 days following resolution of symptoms. All the samples were initially screened by the Ortho Total Ig test to confirm positivity and subsequently tested with 7 additional direct sandwich or indirect binding assays (Ortho, Roche, Abbott, Broad Institute) directed against a variety of antigen targets (S1, RBD, and NC), along with 2 neutralization assays (Broad Institute live virus PRNT and Vitalant Research Institute Pseudovirus RVPN). Results The direct detection assays (Ortho Total Ig total and Roche Total Ig) showed increasing levels of antibodies over the time period, in contrast to the indirect IgG assays that showed a decline. Neutralization assays also demonstrated declining responses; the VRI RVPN pseudovirus had a greater rate of decline than the Broad PRNT live virus assay. Discussion These data show that in addition to variable individual responses and associations with disease severity, the detection assay chosen contributes to the heterogeneous results in antibody stability over time. Depending on the scope of the research, one assay may be preferable over another. For serosurveillance studies, direct, double Ag-sandwich assays appear to be the best choice due to their stability; in particular, algorithms that include both S1 and NC based assays can help reduce the rate of false-positivity and discriminate between natural infection and vaccine-derived seroreactivity. In the past several months, research on Coronavirus Disease 2019 (COVID- 19) immune response has confirmed that the majority of infected individuals mount antibody responses to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes the disease. 1 Increasing evidence suggests that more rapid and potent humoral responses correlate with the severity of disease, 2, 3 likely due to greater and longer exposure to the viral antigen. The antibody response to acute viral infections typically declines from peak titers following recovery from acute infection. Conflicting reports have described the rapidity of antibody decline following SARS-CoV-2 infection, with some studies reporting a rapid decay of anti-SARS-CoV-2 antibodies, 3,4,5,6 while others have described stable short-term responses 7 or even a sustained response, up to 8 months after infection. 8 In keeping with the strength of the initial humoral response correlating with severity of disease, many of the studies demonstrating rapid waning of anti-viral responses have been performed in asymptomatic individuals or patients with mild symptoms. Indeed, in a direct comparison, antibodies decayed more rapidly in mild cases compared to severe infection. 9 This finding is in line with previous studies for other coronaviruses. 10 However, there is also evidence that some of the variability seen in these studies is due to the serological assays deployed. 8 Different antibody isotypes, antibodies targeting different antigens and epitopes, and different assay formats (indirect, direct), are likely to wane with differing kinetics, making some immunoassay approaches more effective than others. The most common commercially available assays target either the spike subunit (S1) that mediates viral entry, the receptor binding domain (RBD) of S1 which binds to its human cellular receptor angiotensin-converting enzyme 2 (ACE2), or the nucleocapsid (NC) protein that encapsulates the viral genome. 11 Using 18 repeat donors of COVID-19 convalescent plasma (CCP) we studied the kinetics of antibody evolution and decline up to 129 days after resolution of COVID-19 symptoms. Eight antibody binding assays on different platforms and targeting different antibody isotypes and viral antigens were investigated, as well as two assays of viral neutralization (Table 1) . This allowed in-depth comparison between assays and antigen targets in order to identify assays that may be suited for different purposes such as serodiagnosis of recently acquired infection, serosurveillance, correlates of immune protection, or potency of CCP. Assays that effectively detect and quantify long-lasting serological responses are important tools for making accurate seroprevalence estimates of previous infection to track incidence over time. Alternately, immunoassays that demonstrate a rapidly waning response may be useful for performing recency studies, identifying hotspots of infection and predicting subsequent protective immunity at the individual and population level (i.e., herd immunity). High-throughput assays waning in parallel with neutralizing antibody response may also be particularly valuable in the characterization of CCP neutralizing antibody content. CCPs were collected in the Vitalant system following FDA Guidance for donor eligibility 12 as previously described. 13 These criteria evolved throughout the study period due to testing availability and evolution of the pandemic in the United States. Evidence of COVID-19 was required in the form of a documented positive SARS-CoV-2 molecular or serologic test, and complete resolution of symptoms initially at least 14 days prior to donation (with a negative molecular test if <28 days), but then a minimum of 28 days was implemented. All CCP donors were also required to meet traditional allogeneic blood donor criteria. At the time of plasma collection, donors consented to use of de-identified donor information and test results for research purposes. Medical Director approval was obtained for CCP collection every 7 days for interested donors. Between April 8 and October 20, 2020, approximately 50,000 units were released from 7976 unique donors. All CCPs were tested for SARS-CoV-2 total Ig antibody using the . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) donations and an interval from the first to last donation of over 60 days. We selected a subset of 19 unique donors for evaluation of the persistence of SARS-CoV-2 Ab with date range from first to last donation 47-99 days (resolution of symptoms to last donation 63-129 days) and 4-12 total donations. One donor was subsequently removed from the analysis set for cause because only 2 retained serum samples were retrievable and these were negative for neutralizing antibody. For the present analysis, donor COVID-19 symptom and SARS-CoV-2 testing histories were reviewed. The time course of longitudinal donations was determined based on the date of resolution of all disease symptoms. The Ortho VITROS Anti-SARS-CoV-2 Total (CoV2T, Ortho-Clinical Diagnostics, Inc., Rochester, NY) was used at CTS to detect total (IgG, IgM and IgA) antibodies against the spike S1 protein, as previously described. 13 Briefly, serum samples are quickly vortexed, loaded on Ortho VITROS XT-7200 or 3600 instruments (Ortho Clinical Diagnostics, Raritan, NJ) and programmed for the CoV2T test following the manufacturer's instructions. 14 The S1 antigens coated on the assay wells bind S1 antibodies from human serum which, in turn, bind to a secondary HRP-labeled S1 antigen in the conjugate reagent forming a sandwich. The addition of signal reagent containing luminol generates a chemiluminescence reaction that is measured by the system and quantified as the ratio of the signal relative to the cut-off value generated during calibration. An S/CO ≥1 is considered positive. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The Elecsys Anti-SARS-CoV-2 immunoassay (Roche NC) was run at CTS on the cobas e441 analyzer Levels of IgG antibodies were measured in plasma by the Ortho VITROS Anti-SARS-CoV-2 IgG (CoV2G, Ortho-Clinical Diagnostics, Inc., Rochester, NY) at Ortho Diagnostics using a quantitative RUA assay. Similar to the VITROS CoV2T, in the first step the antibodies present in the specimen bind to the S1 spike on the testing wells. However, in the following stage, HRP-conjugated murine monoclonal anti-human IgG antibodies are added, targeting the antibody portion of the complex. When the luminogenic substrate is added, chemiluminescence is then measured and quantified as a S/CO, with values above 1 considered positive. 16 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 26, 2021. ; https://doi.org/10.1101/2021.03.24.21254260 doi: medRxiv preprint A qualitative SARS-CoV-2 IgG assay targeting IgG against nucleocapsid protein was performed by Abbott (Architect NC IgG, Abbott Diagnostics, Abbott Park, IL) on the Architect platform using chemiluminescent microparticle immunoassay (CMIA) technology. 17 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 26, 2021. ; https://doi.org/10.1101/2021.03.24.21254260 doi: medRxiv preprint nm and 570 nm on a BioTek Synergy HT. For control antibodies CR3022 IgG1 and IgM (Absolute Antibody) dilution curves, the antibodies were diluted to a concentration of 1μg/mL in dilution buffer and duplicate 12 two-fold serial dilution curves were generated. Sample concentrations were estimated based on the standard curve. Live-virus SARS-CoV-2 antibody neutralization was performed at Broad Institute on a high throughput platform (BROAD PRNT). Vero E6-TMPRSS2 were seeded at 10,000 cells per well the day prior to infection in a CellCarrier-384 ultra-microplate (Perkin Elmer). Patient serum samples were tested at a starting dilution of 1:40 and were serially diluted 2-fold up to eight dilution spots. Serially diluted patient sera were mixed separately with diluted SARS-CoV-2 live virus (D614) and incubated at 37°C with 5% CO2 for 1 hour; after which the sera-virus complexes were added to the Vero E6-TMPRSS2 cells and incubated at 37°C with 5% CO2 for 48 hours. Cells were then fixed using 4% paraformaldehyde in PBS for 2 hours at room temperature, washed, and incubated with diluted anti-SARS-CoV/SARS-CoV-2 nucleoprotein mouse antibody (Sino Biological) for 1.5 hours at room temperature. They were subsequently incubated with Alexa488-conjugated goat anti-mouse (Jackson ImmunoResearch Labs) for 45 mins at room temperature, followed by nuclear staining with Hoechst 33342 (Thermo Fisher Scientific). Fluorescence imaging was performed using the Opera Phenix™ High Content Screening System (Perkin Elmer). Half-maximal inhibitory dilutions (ID50) were determined using a fourparameter, nonlinear curve fitting algorithm. Samples whose curves lay above 0.5 for all the data points were considered non-neutralizing, with ID50=20, while samples whose curves fell below 0.5 were considered highly neutralizing and assigned an ID50=10,240. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) Serum samples were tested at VRI for SARS-CoV-2 reporter viral particle neutralization (RVPN) as previously described 13, 18, 19 To determine if the sample selected was representative of the total number of donors with multiple donations over the period, we evaluated the Ortho VITROS CoV2T signal over time from first donation for the 275 donors with >60d maximum observation period at >4 donations. These data were evaluated by regression as described above and compared to the subset of 18 subjects chosen for this study. This study accessed longitudinal samples from CCP donors with intervals between resolution of disease symptoms and last donation of 63-129 days and 3-12 total donations per donor to evaluate and compare the persistence of antibody reactivity of 10 SARS-CoV-2 antibody assays. These assays included six commercial assays with different antigen targets (S1, RBD, NC) and detection formats (direct detection by antigen labeled conjugate; indirect detection using anti-human IgG labeled conjugate), S1 RBD and NC-based assays developed at the Broad Institute, and live and pseudovirus-based neutralization assays. These assays represent the diversity of tests employed for serodiagnosis, serosurveillance, and characterization of levels of binding and neutralizing activity for assessment of efficacy of passive immunotherapies (CCP, monoclonal antibodies, hyperimmune IgG preparations), . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. have also correlated the waning of binding assay reactivities, and particularly IgG assays with S1, RBD and NC antigens, relative to waning neutralizing antibodies to identify high throughput and low cost assays that could serve as proxies for live virus PRNT or pseudovirus RVPNT assays. 13, 21 These analyses have demonstrated variable correlations and predictive values of S1, RBD and NC-based immunoassays with waning neutralizing activity. The first high throughput test designated by the US FDA for use in labeling CCP with high-or low-titer antibody content was the Ortho CoV2G IgG assay. Notably, the Abbott Architect SARS-CoV-2 IgG and Ortho Vitros Anti-SARS-CoV-2 IgG assays used in the present study, were among those found acceptable for this purpose. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 26, 2021. ; https://doi.org/10.1101/2021.03.24.21254260 doi: medRxiv preprint For serosurveillance studies, which have been widely implemented regionally, nationally and internationally to monitor SARS-CoV-2 transmission dynamics using serial cross-sectional sample sets from populations including blood donors, the preferred assay(s) would have sustained antibody reactivity over at least six months and optimally longer to accurately track cumulative incidence. 19, 22, 23 If assays that are susceptible to rapid waning of seroreactivity are employed in serosurveillance studies, significant proportions of previously infected persons could have seroreverted in downstream waves of sample collection and testing. 24 Such waning can be addressed by statistical adjustments in analyses, based on patterns of waning using CCP sample sets of findings from serial cross-sectional results, as recently done in a large study from Brazil based on the Abbott NC IgG assay included in the present study. 25 But these adjustments require parallel data on waning profiles, are complex, and have led to debate over the validity and generalizability of serosurveillance findings in studies employing assays that demonstrate antibody waning. In contrast, the direct antigen sandwich assays that we evaluated, which included the S1-based Total Ig assay from Ortho and NC-based Total Ig assay from Roche, are optimal for application in serosurveillance studies given the stability and even increasing levels of reactivity observed over time, presumably due to continued maturation of antibody affinity and/or avidity resulting in increasing signal intensity in these assays. 26, 27 The pattern of persistence and even increasing reactivity of these assays which we observed with serial convalescent plasma donations has also been observed in analyses of serial donations by regular blood donors screened with these assays and by another antigen sandwich configuration assay by Wantai. 28 Moreover, by combining S-and NCbased direct antigen sandwich assays into algorithms for confirmation of seroreactivity it is possible to minimize the potential contribution of false positive results to estimates of cumulative incidence of natural infections over time and across regional and demographic subgroups. This algorithm has been adopted in the US REDS-IV-P RESPONSE and National Blood Donor Serosurveillance Studies (MASS-BD). . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 26, 2021. ; https://doi.org/10.1101/2021.03.24.21254260 doi: medRxiv preprint As SARS-CoV-2 vaccines are being rapidly approved and implemented to mitigate the pandemic, there will be a need for combinations of S-and NC-based assays or multiplexed S/RBD/NC assays to detect and discriminate antibodies induced by natural infection from vaccine induced seropositivity (VISP). Assays/algorithms will also be needed to monitor vaccine penetrance and persistence of VISP, as well as to detect breakthrough infections in vaccinated persons following ongoing exposures to SARS-CoV-2. The algorithm adopted for the US National Blood Donor Serosurveillance Study (MASS-BD) that employs the Ortho CoV2T Total Ig assay followed by the Roche NC Total Ig assay on all S1 antibody reactive samples should allow for simultaneous and accurate detection of VISP and natural infection induced seropositivity, and has the potential to surveil for vaccine breakthrough infections in longitudinal databases of repeat blood donors who were determined to be previously vaccinated. Measuring antibody levels over time within populations, including CCP and routine blood donors, may also provide valuable data on risk of reinfections. Reinfections will likely induce anamnestic boosting of antibody reactivity to both S and NC antigens. 29 Such boosting will be particularly apparent with assays that are prone to waning, such as the Abbott NC and RBD IgG assays and pseudovirus RVPNT assay. Hence different assays and different combinations of SARS-CoV-2 antibody assays will be needed to address the multiple important questions that are arising as the pandemic and mitigation strategies evolve. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Table 1 for assay descriptions. 2A: Indirect detection method assays using anti-IgG secondary antibodies 2B: Left panels -Direct detection method assays using SARS-CoV-2 antigen detection Right panels -neutralizing antibody assays Table 1 for assay descriptions. 2A: Indirect detection method assays using anti-IgG secondary antibodies 2B: Left panels -Direct detection method assays using SARS-CoV-2 antigen detection Right panels -neutralizing antibody assays . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 26, 2021 Antibody responses to SARS-CoV-2 in patients with COVID-19 Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19 Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19 Change in Antibodies to SARS-CoV-2 Over 60 Days Among Health Care Personnel in Waning of SARS-CoV-2 RBD antibodies in longitudinal convalescent plasma samples within 4 months after symptom onset Robust neutralizing antibodies to SARS-CoV-2 infection persist for months Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection Waning Antibody Responses in Asymptomatic and Symptomatic SARS-CoV-2 Infection The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection Food and Drug Administration Food and Drug Administration. Investigational COVID-19 Convalescent Plasma; Guidance for Industry Selecting COVID-19 convalescent plasma for neutralizing antibody potency using a high-capacity SARS-CoV-2 antibody assay VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total Reagent Pack and VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total Calibrator Instructions for Use. Version 3.0. Ortho Clinical Diagnostics Instructions for Use Version 1.0. Roche Diagnostics GmbH VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG Reagent Pack and VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG Calibrator Instructions for Use. Version 4.2. Ortho Clinical Diagnostics Architect SARS-CoV-2 IgG Instructions for Use. G90418R01. Abbott Laboratories Diagnostics Division SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay Convalescent plasma anti-SARS-CoV-2 spike protein ectodomain and receptor-binding domain IgG correlate with virus neutralization Seroprevalence of Antibodies to SARS-CoV-2 in 10 Sites in the United States Cumulative incidence and diagnosis of SARS-CoV-2 infection in New York Estimating the cumulative incidence of SARS-CoV-2 infection and the infection fatality ratio in light of waning antibodies Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic Cross-Neutralization of a SARS-CoV-2 Antibody to a Functionally Conserved Site Is Mediated by Avidity SARS-CoV-2 Antibody Avidity Responses in COVID-19 Patients and Convalescent Plasma Donors An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment The Importance and Challenges of Identifying SARS-CoV-2 Reinfections Abbott Diagnostics & Ortho-Clinical Diagnostics kindly provided reagents and testing services for their assay platforms. Thanks and acknowledgements also are extended to the extended teams at Vitalant Research Institute and the Broad Institute that managed sample procurement, preparation, testing, and data verification.